Read the results of the vaccine equity study in Sickle Cell Disease conducted by SCAGO, funded by the Public Health Agency of Canada

The Sickle Cell Awareness Group of Ontario (SCAGO) is pleased with the news of CASGEVY (Exagamglogene Autotemcel) receiving marketing authorization for the treatment of Sickle Cell and Thalassemia disorders in Canada.

Pfizer Inc. announced today that it is voluntarily withdrawing all lots of OXBRYTA ® (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is approved.

A guide to understanding sickle cell disease and what it means for your child.

Improving the knowledge of peers and families about blood transfusion in sickle cell disease